Therefore, we followed up by using shRNA knock-down in melanoma cells to target the hits identified from our CRISPR KO screen (ST3GAL5, B4GALT5, UGCG, p < 0.05, FDR < 0.2). This evidence concerns the gene B4GALT5 and melanoma.